

FORMA Therapeutics Named by FierceBiotech in the 2011 Fierce 15

CAMBRIDGE, Mass. – September 6, 2011 – [FORMA Therapeutics](#) was named by FierceBiotech today as one of the 2011 Fierce 15, designating it as one of the most promising private biotechnology companies in the industry.

“While the virtual trend in biotech keeps growing in strength, FORMA Therapeutics is going its own way,” says John Carroll, editor-in-chief of FierceBiotech. “The developer has built a sizable discovery group with operations around the globe. And it’s been able to use some of its early discoveries in tumor metabolism to forge significant new partnerships with industry leaders that break new ground on deal terms. As long as CEO Steven Tregay’s group can continue to sign up big partners, its future in cancer drug development will remain bright. And they show no signs of letting up.”

“The employees of FORMA are excited and honored by the Fierce 15 award,” said Steven Tregay, CEO of FORMA. “The quality and uniqueness of our approach has been recognized throughout the industry by potential collaborators and investors.”

Kenneth Bair, Head of R&D of FORMA added, “We continue to evolve our fully integrated drug discovery platform to create innovative drugs across important cancer target families. The efficiency of the FORMA discovery engine allows rapid prioritization and decision making to create a robust pipeline.”

An internationally recognized daily newsletter reaching more than 90,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick, authoritative briefing on the day's top stories. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. A complete list of “Fierce 15” companies—the online newsletter’s ninth annual selection—is available online at www.fiercebiotech.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at <http://www.fiercebiotech.com>.

About FORMA Therapeutics

FORMA Therapeutics unlocks intractable targets to create transformative small molecule therapies in oncology. FORMA is creating a pipeline of products by applying its proprietary cell-based screening, structure-guided drug discovery and Diversity Oriented Synthesis (DOS) technologies. FORMA also uses its discovery technology to create novel compounds for its partners in many therapeutic areas. FORMA is headquartered in Cambridge, MA with additional research operations in Connecticut and Singapore. www.formatherapeutics.com

FORMA Therapeutics

Steven Tregay, CEO

(617) 679-1970

or

Media Inquiries

MacDougall Biomedical Communications

Kari Watson

(781) 235-3060

kwatson@macbiocom.com